(Q43719042)

26 November 2017

title

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study (English)

1 reference

26 November 2017

C Waldherr

1

1 reference

26 November 2017

M Pless

2

1 reference

26 November 2017

H R Maecke

3

1 reference

26 November 2017

A Haldemann

4

1 reference

26 November 2017

J Mueller-Brand

5

1 reference

26 November 2017

publication date

1 July 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

12

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

941-945

1 reference

The glucagonoma syndrome: Surgically curable diabetes

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Somatostatin-receptor imaging in the localization of endocrine tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Empiric chemotherapy in patients with carcinoma of unknown primary site

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011160913619

7 January 2021

Identifiers

DOI

10.1023/A:1011160913619

1 reference

26 November 2017

1 reference